{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:06:49Z","timestamp":1792004809223,"version":"4.4.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04238-1","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:34:40Z","timestamp":1770363280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating tumor DNA\u2013guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities"],"prefix":"10.1186","volume":"24","author":[{"given":"Ruoyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuopeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"3","key":"4238_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4238_CR2","doi-asserted-by":"publisher","first-page":"776863","DOI":"10.3389\/fonc.2021.776863","volume":"11","author":"Y Bekki","year":"2021","unstructured":"Bekki Y, et al. Recurrent intrahepatic Cholangiocarcinoma - Review. Front Oncol. 2021;11:776863.","journal-title":"Front Oncol"},{"issue":"10272","key":"4238_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, et al. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"11","key":"4238_CR4","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"key":"4238_CR5","doi-asserted-by":"publisher","first-page":"100092","DOI":"10.1016\/j.esmogo.2024.100092","volume":"5","author":"T Goetze","year":"2024","unstructured":"Goetze T, et al. New perspectives in biliary tract cancers. ESMO Gastrointest Oncol. 2024;5:100092.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"1","key":"4238_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12876-022-02637-8","volume":"22","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, et al. The epidemiological trends of biliary tract cancers in the united States of America. BMC Gastroenterol. 2022;22(1):546.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"4238_CR7","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, et al. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156(7):2024\u201340.","journal-title":"Gastroenterology"},{"issue":"8","key":"4238_CR8","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1245\/s10434-018-6558-7","volume":"25","author":"VP Groot","year":"2018","unstructured":"Groot VP, et al. Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25(8):2475.","journal-title":"Ann Surg Oncol"},{"key":"4238_CR9","doi-asserted-by":"crossref","unstructured":"Jacobsen A et al. Impact of structured postoperative surveillance on survival in patients with resected pancreatic adenocarcinoma. Cancers (Basel). 2025;17(9):1103.","DOI":"10.3390\/cancers17091424"},{"issue":"6","key":"4238_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.pan.2024.07.017","volume":"24","author":"M Brunner","year":"2024","unstructured":"Brunner M, et al. Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients. Pancreatology. 2024;24(6):930\u20137.","journal-title":"Pancreatology"},{"issue":"1","key":"4238_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000513711","volume":"37","author":"H Lang","year":"2021","unstructured":"Lang H. Surgical approach to recurrent cholangiocarcinoma. Visc Med. 2021;37(1):26\u201331.","journal-title":"Visc Med"},{"issue":"2","key":"4238_CR12","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19\u2009\u2013\u20099 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105\u201319.","journal-title":"J Gastrointest Oncol"},{"key":"4238_CR13","doi-asserted-by":"crossref","unstructured":"Ramaekers M et al. Computer-Aided detection for pancreatic cancer diagnosis: radiological challenges and future directions. J Clin Med. 2023;12(13):3565.","DOI":"10.3390\/jcm12134209"},{"issue":"7","key":"4238_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-22-3526","volume":"29","author":"M Lapin","year":"2023","unstructured":"Lapin M, et al. Comprehensive ctdna measurements improve prediction of clinical outcomes and enable dynamic tracking of disease progression in advanced pancreatic cancer. Clin Cancer Res. 2023;29(7):1267\u201378.","journal-title":"Clin Cancer Res"},{"key":"4238_CR15","doi-asserted-by":"crossref","unstructured":"Jaworski JJ, Morgan RD, Sivakumar S. Circulating Cell-Free Tumour DNA Early Detect Pancreat Cancer Cancers (Basel). 2020;12(12):1592.","DOI":"10.3390\/cancers12123704"},{"issue":"5","key":"4238_CR16","doi-asserted-by":"publisher","first-page":"e0322720","DOI":"10.1371\/journal.pone.0322720","volume":"20","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, et al. The role of novel biomarkers in the early diagnosis of pancreatic cancer: A systematic review and meta-analysis. PLoS ONE. 2025;20(5):e0322720.","journal-title":"PLoS ONE"},{"key":"4238_CR17","doi-asserted-by":"crossref","unstructured":"\u00dclg\u00fc MM, Birinci \u015e. Utilization and effectiveness of the CA 19\u2009\u2013\u20099 test for cancer diagnosis: insights from health ministry records. Istanbul Med J. 2023;24:12\u20138.","DOI":"10.4274\/imj.galenos.2023.75428"},{"issue":"8","key":"4238_CR18","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10620-011-1709-8","volume":"56","author":"S Singh","year":"2011","unstructured":"Singh S, et al. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56(8):2491\u20136.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"4238_CR19","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1007\/s00261-025-04831-0","volume":"50","author":"RR Ryu","year":"2025","unstructured":"Ryu RR, et al. Small pancreatic ductal adenocarcinoma (\u2264\u20092\u00a0cm): different imaging and clinicopathologic features according to extrapancreatic extension. Abdom Radiol (NY). 2025;50(9):4168\u201380.","journal-title":"Abdom Radiol (NY)"},{"issue":"19","key":"4238_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","volume":"24","author":"L Zhang","year":"2018","unstructured":"Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047\u201360.","journal-title":"World J Gastroenterol"},{"key":"4238_CR21","doi-asserted-by":"publisher","first-page":"1631671","DOI":"10.3389\/fmed.2025.1631671","volume":"12","author":"X Yu","year":"2025","unstructured":"Yu X, et al. Combining multimodal medical imaging and artificial intelligence for the early diagnosis of pancreatic cancer. Front Med (Lausanne). 2025;12:1631671.","journal-title":"Front Med (Lausanne)"},{"key":"4238_CR22","doi-asserted-by":"publisher","first-page":"1520717","DOI":"10.3389\/fonc.2025.1520717","volume":"15","author":"M Cox","year":"2025","unstructured":"Cox M, Vitello D, Chawla A. Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma. Front Oncol. 2025;15:1520717.","journal-title":"Front Oncol"},{"key":"4238_CR23","doi-asserted-by":"publisher","first-page":"1303335","DOI":"10.3389\/fonc.2024.1303335","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335.","journal-title":"Front Oncol"},{"key":"4238_CR24","doi-asserted-by":"crossref","unstructured":"Lin C et al. Liquid Biopsy, ctdna diagnosis through NGS. Life (Basel). 2021;11(9):1264.","DOI":"10.3390\/life11090890"},{"key":"4238_CR25","doi-asserted-by":"publisher","first-page":"1616064","DOI":"10.3389\/fcell.2025.1616064","volume":"13","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives. Front Cell Dev Biol. 2025;13:1616064.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"4238_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.21873\/cgp.20203","volume":"17","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteom. 2020;17(5):441\u201352.","journal-title":"Cancer Genomics Proteom"},{"key":"4238_CR27","doi-asserted-by":"publisher","first-page":"NA","DOI":"10.20517\/2394-4722.2022.20","volume":"8","author":"Z Tyerman","year":"2022","unstructured":"Tyerman Z, et al. Utility of Circulating tumor DNA for predicting prognosis in the management of resectable pancreatic cancer. J Cancer Metastasis Treat. 2022;8:NA\u2013NA.","journal-title":"J Cancer Metastasis Treat"},{"key":"4238_CR28","doi-asserted-by":"publisher","first-page":"175883592311576","DOI":"10.1177\/17588359231157651","volume":"15","author":"JT Topham","year":"2023","unstructured":"Topham JT, Renouf DJ, Schaeffer DF. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma. Ther Adv Med Oncol. 2023;15:17588359231157651.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"4238_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pan.2020.12.017","volume":"21","author":"L Sivapalan","year":"2021","unstructured":"Sivapalan L, et al. Molecular profiling of ctdna in pancreatic cancer: opportunities and challenges for clinical application. Pancreatology. 2021;21(2):363\u201378.","journal-title":"Pancreatology"},{"key":"4238_CR30","doi-asserted-by":"publisher","first-page":"105109","DOI":"10.1016\/j.ebiom.2024.105109","volume":"103","author":"J Zheng","year":"2024","unstructured":"Zheng J, et al. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis. EBioMedicine. 2024;103:105109.","journal-title":"EBioMedicine"},{"key":"4238_CR31","doi-asserted-by":"crossref","unstructured":"Dubrovsky G et al. Liquid biopsy in pancreatic ductal adenocarcinoma: A review of methods and applications. Int J Mol Sci. 2024;25(20):10967.","DOI":"10.3390\/ijms252011013"},{"key":"4238_CR32","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. Correlative analysis of tumor-Informed Circulating tumor DNA (ctDNA) and the survival outcomes of patients with pancreatic adenocarcinoma. Biomedicines. 2025;13(5):1049.","DOI":"10.3390\/biomedicines13051124"},{"key":"4238_CR33","doi-asserted-by":"crossref","unstructured":"Quan PL, Sauzade M, Brouzes E. dPCR: Technol Rev Sens (Basel). 2018;18(4):1271.","DOI":"10.3390\/s18041271"},{"issue":"5","key":"4238_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40291-017-0278-8","volume":"21","author":"S Olmedillas-L\u00f3pez","year":"2017","unstructured":"Olmedillas-L\u00f3pez S, Garc\u00eda-Arranz M, Garc\u00eda-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21(5):493\u2013510.","journal-title":"Mol Diagn Ther"},{"issue":"13","key":"4238_CR35","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/cncr.29364","volume":"121","author":"H Kinugasa","year":"2015","unstructured":"Kinugasa H, et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. 2015;121(13):2271\u201380.","journal-title":"Cancer"},{"key":"4238_CR36","doi-asserted-by":"crossref","unstructured":"Zavrtanik \u010carni H et al. Somatic mutation detection in tumor tissue and matched Cell-Free DNA using PCR-Based methods in pancreatic cancer patients undergoing upfront resection. Int J Mol Sci. 2025;26(17):8966.","DOI":"10.3390\/ijms26178518"},{"issue":"15","key":"4238_CR37","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.1133470100","volume":"100","author":"D Dressman","year":"2003","unstructured":"Dressman D, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"4238_CR38","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985\u201390.","journal-title":"Nat Med"},{"issue":"3","key":"4238_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/gcc.22517","volume":"57","author":"AL Volckmar","year":"2018","unstructured":"Volckmar AL, et al. A field guide for cancer diagnostics using cell-free DNA: from principles to practice and clinical applications. Genes Chromosomes Cancer. 2018;57(3):123\u201339.","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"4238_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297\u2013312.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7540","key":"4238_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501.","journal-title":"Nature"},{"issue":"9","key":"4238_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003\u201310.","journal-title":"Nat Genet"},{"issue":"6127","key":"4238_CR43","first-page":"1546","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, et al. Cancer Genome Landscapes Sci. 2013;339(6127):1546\u201358.","journal-title":"Cancer Genome Landscapes Sci"},{"issue":"4","key":"4238_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, et al. Liquid biopsies come of age: towards implementation of Circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"4238_CR45","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, et al. Minimal residual disease detection using a Plasma-only Circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586\u201394.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4238_CR46","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, et al. Analysis of plasma Cell-Free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124\u201331.","journal-title":"JAMA Oncol"},{"issue":"16","key":"4238_CR47","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","volume":"25","author":"VP Groot","year":"2019","unstructured":"Groot VP, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res. 2019;25(16):4973\u201384.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4238_CR48","doi-asserted-by":"publisher","first-page":"105079","DOI":"10.1016\/j.esmoop.2025.105079","volume":"10","author":"M de Scordilli","year":"2025","unstructured":"de Scordilli M, et al. Precision oncology in biliary tract cancer: the emerging role of liquid biopsy. ESMO Open. 2025;10(5):105079.","journal-title":"ESMO Open"},{"issue":"10","key":"4238_CR49","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"4238_CR50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745\u201359.","journal-title":"Ann Oncol"},{"issue":"4","key":"4238_CR51","first-page":"639","volume":"73","author":"R Ben-Ami","year":"2024","unstructured":"Ben-Ami R, et al. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024;73(4):639\u201348.","journal-title":"Gut"},{"issue":"8","key":"4238_CR52","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/hep4.1730","volume":"5","author":"JD Yang","year":"2021","unstructured":"Yang JD, et al. DNA methylation markers for detection of cholangiocarcinoma: Discovery, Validation, and clinical testing in biliary brushings and plasma. Hepatol Commun. 2021;5(8):1448\u201359.","journal-title":"Hepatol Commun"},{"issue":"1","key":"4238_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13148-019-0634-0","volume":"11","author":"W Wasenang","year":"2019","unstructured":"Wasenang W, et al. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that May aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clin Epigenetics. 2019;11(1):39.","journal-title":"Clin Epigenetics"},{"issue":"3","key":"4238_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-021-01635-z","volume":"126","author":"Y Liu","year":"2022","unstructured":"Liu Y. At the dawn: cell-free DNA fragmentomics and gene regulation. Br J Cancer. 2022;126(3):379\u201390.","journal-title":"Br J Cancer"},{"issue":"7761","key":"4238_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385\u20139.","journal-title":"Nature"},{"key":"4238_CR56","unstructured":"Mouliere F et al. Enhanced detection of Circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921."},{"issue":"6378","key":"4238_CR57","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926\u201330.","journal-title":"Science"},{"issue":"38","key":"4238_CR58","doi-asserted-by":"publisher","first-page":"10202","DOI":"10.1073\/pnas.1704961114","volume":"114","author":"JD Cohen","year":"2017","unstructured":"Cohen JD, et al. Combined Circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017;114(38):10202\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4238_CR59","doi-asserted-by":"publisher","first-page":"2403334","DOI":"10.1080\/20450923.2024.2403334","volume":"11","author":"JA Awosika","year":"2024","unstructured":"Awosika JA, Monge C, Greten TF. Integration of Circulating tumor DNA in biliary tract cancer: the emerging landscape. Hepat Oncol. 2024;11(1):2403334.","journal-title":"Hepat Oncol"},{"issue":"2","key":"4238_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659\u2013702.","journal-title":"Hepatology"},{"issue":"1","key":"4238_CR61","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cld.2023.07.010","volume":"28","author":"D Saca","year":"2024","unstructured":"Saca D, Flamm SL. Cholangiocarcinoma surveillance recommendations in patients with primary sclerosing cholangitis. Clin Liver Dis. 2024;28(1):183\u201392.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"4238_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/hep.32125","volume":"75","author":"HM Vedeld","year":"2022","unstructured":"Vedeld HM, et al. Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology. 2022;75(1):59\u201373.","journal-title":"Hepatology"},{"issue":"7","key":"4238_CR63","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/cancers17071243","volume":"17","author":"N Nishida","year":"2025","unstructured":"Nishida N. Biomarkers and management of cholangiocarcinoma: unveiling new horizons for precision therapy. Cancers. 2025;17(7):1243.","journal-title":"Cancers"},{"issue":"19","key":"4238_CR64","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","volume":"30","author":"A Gonz\u00e1lez-Medina","year":"2024","unstructured":"Gonz\u00e1lez-Medina A, et al. Clinical value of liquid biopsy in patients with FGFR2 Fusion-Positive cholangiocarcinoma during targeted therapy. Clin Cancer Res. 2024;30(19):4491\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4238_CR65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang S, et al. Concordance of ctdna and tissue genomic profiling in advanced biliary tract cancer. J Hepatol. 2025;82(4):649\u201357.","journal-title":"J Hepatol"},{"issue":"224","key":"4238_CR66","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, et al. Detection of Circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.","journal-title":"Sci Transl Med"},{"issue":"1","key":"4238_CR67","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-024-03166-w","volume":"43","author":"KL Reese","year":"2024","unstructured":"Reese KL, Pantel K, Smit DJ. Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review. J Exp Clin Cancer Res. 2024;43(1):250.","journal-title":"J Exp Clin Cancer Res"},{"key":"4238_CR68","doi-asserted-by":"publisher","first-page":"918795","DOI":"10.3389\/fcell.2022.918795","volume":"10","author":"J G\u00f6tze","year":"2022","unstructured":"G\u00f6tze J, et al. Tumor-Stroma interaction in PDAC as a new approach for liquid biopsy and its potential clinical implications. Front Cell Dev Biol. 2022;10:918795.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"4238_CR69","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding EJ, et al. Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968\u201386.","journal-title":"Cancer Discov"},{"issue":"1","key":"4238_CR70","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336.","journal-title":"Signal Transduct Target Ther"},{"key":"4238_CR71","doi-asserted-by":"crossref","unstructured":"Constantin N et al. Opportunities for early cancer detection: the rise of ctdna Methylation-Based Pan-Cancer screening technologies. Epigenomes. 2022;6(1):7.","DOI":"10.3390\/epigenomes6010006"},{"key":"4238_CR72","doi-asserted-by":"crossref","unstructured":"de Jesus VHF et al. Targeting KRAS in pancreatic ductal adenocarcinoma: the long road to cure. Cancers (Basel). 2023;15(20):5268.","DOI":"10.3390\/cancers15205015"},{"key":"4238_CR73","doi-asserted-by":"crossref","unstructured":"Mercanti L et al. PDAC, the influencer cancer: Cross-Talk with tumor microenvironment and connected potential therapy strategies. Cancers (Basel). 2023;15(11):2869.","DOI":"10.3390\/cancers15112923"},{"issue":"4","key":"4238_CR74","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","volume":"142","author":"M Kanda","year":"2012","unstructured":"Kanda M, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142(4):730\u2013e7339.","journal-title":"Gastroenterology"},{"key":"4238_CR75","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.ctrv.2023.102649","volume":"122","author":"A Stenzinger","year":"2024","unstructured":"Stenzinger A, et al. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing. Cancer Treat Rev. 2024;122:102649.","journal-title":"Cancer Treat Rev"},{"key":"4238_CR76","doi-asserted-by":"crossref","unstructured":"Oura K et al. Chronic liver disease associated cholangiocarcinoma: genomic insights and precision therapeutic strategies. Cancers (Basel). 2025;17(18):2416.","DOI":"10.3390\/cancers17183052"},{"issue":"26","key":"4238_CR77","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"12","key":"4238_CR78","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi P, et al. High-intensity sequencing reveals the sources of plasma Circulating cell-free DNA variants. Nat Med. 2019;25(12):1928\u201337.","journal-title":"Nat Med"},{"issue":"36","key":"4238_CR79","doi-asserted-by":"publisher","first-page":"eabh0534","DOI":"10.1126\/sciadv.abh0534","volume":"7","author":"P Siejka-Zieli\u0144ska","year":"2021","unstructured":"Siejka-Zieli\u0144ska P, et al. Cell-free DNA TAPS provides multimodal information for early cancer detection. Sci Adv. 2021;7(36):eabh0534.","journal-title":"Sci Adv"},{"issue":"10","key":"4238_CR80","doi-asserted-by":"publisher","first-page":"103706","DOI":"10.1016\/j.esmoop.2024.103706","volume":"9","author":"L Kehmann","year":"2024","unstructured":"Kehmann L, et al. Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets. ESMO Open. 2024;9(10):103706.","journal-title":"ESMO Open"},{"issue":"1","key":"4238_CR81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","volume":"23","author":"D Pietrasz","year":"2017","unstructured":"Pietrasz D, et al. Plasma Circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017;23(1):116\u201323.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4238_CR82","doi-asserted-by":"publisher","first-page":"103687","DOI":"10.1016\/j.esmoop.2024.103687","volume":"9","author":"R Cutts","year":"2024","unstructured":"Cutts R, et al. Association of post-operative ctdna detection with outcomes of patients with early breast cancers. ESMO Open. 2024;9(9):103687.","journal-title":"ESMO Open"},{"issue":"1","key":"4238_CR83","doi-asserted-by":"publisher","first-page":"16971","DOI":"10.1038\/s41598-019-53271-6","volume":"9","author":"JS Lee","year":"2019","unstructured":"Lee JS, et al. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Sci Rep. 2019;9(1):16971.","journal-title":"Sci Rep"},{"issue":"1","key":"4238_CR84","doi-asserted-by":"publisher","first-page":"27296","DOI":"10.1038\/s41598-024-76903-y","volume":"14","author":"C Maulat","year":"2024","unstructured":"Maulat C, et al. Prognostic impact of Circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Sci Rep. 2024;14(1):27296.","journal-title":"Sci Rep"},{"issue":"1","key":"4238_CR85","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12935-025-03894-9","volume":"25","author":"K Miyamoto","year":"2025","unstructured":"Miyamoto K, et al. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Cancer Cell Int. 2025;25(1):305.","journal-title":"Cancer Cell Int"},{"key":"4238_CR86","doi-asserted-by":"crossref","unstructured":"Du J, et al. Personalized ctdna monitoring to assess the recurrence of early stage pancreatic cancer after surgery. Am Soc Clin Oncol. 2025;43(16_sup):416.","DOI":"10.1200\/JCO.2025.43.4_suppl.774"},{"key":"4238_CR87","doi-asserted-by":"crossref","unstructured":"Wang X, et al. Patient-specific tumor-informed Circulating tumor DNA (ctDNA) assay to predict cancer recurrence in patients with resected pancreatic cancer. Am Soc Clin Oncol. 2023;41(16_suppl):4166.","DOI":"10.1200\/JCO.2023.41.4_suppl.744"},{"issue":"9","key":"4238_CR88","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-24-3200","volume":"31","author":"TV Henriksen","year":"2025","unstructured":"Henriksen TV, et al. Timing of ctdna analysis aimed at guiding adjuvant treatment in colorectal cancer. Clin Cancer Res. 2025;31(9):1676\u201385.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4238_CR89","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla M, et al. Using Circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846\u201357.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4238_CR90","doi-asserted-by":"publisher","first-page":"100116","DOI":"10.1016\/j.soi.2024.100116","volume":"2","author":"EM Dickey","year":"2025","unstructured":"Dickey EM, et al. Utility of tumor-informed Circulating tumor DNA for detection of minimal residual disease after curative-intent therapy in localized pancreatic cancer. Surg Oncol Insight. 2025;2(1):100116.","journal-title":"Surg Oncol Insight"},{"issue":"5","key":"4238_CR91","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/bjc.2017.479","volume":"118","author":"Y Nakano","year":"2018","unstructured":"Nakano Y, et al. KRAS mutations in cell-free DNA from preoperative and postoperative Sera as a pancreatic cancer marker: a retrospective study. Br J Cancer. 2018;118(5):662\u20139.","journal-title":"Br J Cancer"},{"issue":"9","key":"4238_CR92","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","volume":"30","author":"B Lee","year":"2019","unstructured":"Lee B, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30(9):1472\u20138.","journal-title":"Ann Oncol"},{"issue":"12","key":"4238_CR93","doi-asserted-by":"publisher","first-page":"e0227366","DOI":"10.1371\/journal.pone.0227366","volume":"14","author":"F Watanabe","year":"2019","unstructured":"Watanabe F, et al. Longitudinal monitoring of KRAS-mutated Circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS ONE. 2019;14(12):e0227366.","journal-title":"PLoS ONE"},{"issue":"24","key":"4238_CR94","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261\u201372.","journal-title":"N Engl J Med"},{"issue":"5","key":"4238_CR95","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","volume":"82","author":"C Yoo","year":"2025","unstructured":"Yoo C, et al. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. J Hepatol. 2025;82(5):861\u201370.","journal-title":"J Hepatol"},{"key":"4238_CR96","doi-asserted-by":"publisher","first-page":"e2400443","DOI":"10.1200\/PO-24-00443","volume":"9","author":"J Yu","year":"2025","unstructured":"Yu J, et al. Detecting early recurrence with Circulating tumor DNA in stage I-III biliary tract cancer after curative resection. JCO Precis Oncol. 2025;9:e2400443.","journal-title":"JCO Precis Oncol"},{"key":"4238_CR97","doi-asserted-by":"crossref","unstructured":"Naleid N, et al. Utilization of Circulating tumor DNA (ctDNA) testing in biliary tract cancers. American Society of Clinical Oncology; 2025;43(3_suppl):591.","DOI":"10.1200\/JCO.2025.43.4_suppl.644"},{"key":"4238_CR98","doi-asserted-by":"crossref","unstructured":"Lapin M, et al. Monitoring of dynamic changes and clonal evolution in Circulating tumor DNA from patients with IDH-Mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors. JCO Precis Oncol. 2022;6:p. e2100197.","DOI":"10.1200\/PO.21.00197"},{"issue":"5","key":"4238_CR99","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509\u201318.","journal-title":"Nat Med"},{"issue":"6","key":"4238_CR100","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4238_CR101","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4238_CR102","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-024-03244-8","volume":"31","author":"Y Nakamura","year":"2025","unstructured":"Nakamura Y, et al. Targeted therapy guided by Circulating tumor DNA analysis in advanced Gastrointestinal tumors. Nat Med. 2025;31(1):165\u201375.","journal-title":"Nat Med"},{"issue":"3","key":"4238_CR103","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3343\/alm.2023.0389","volume":"44","author":"JS Lee","year":"2024","unstructured":"Lee JS, et al. Clinical practice guideline for Blood-based Circulating tumor DNA assays. Ann Lab Med. 2024;44(3):195\u2013209.","journal-title":"Ann Lab Med"},{"issue":"3","key":"4238_CR104","doi-asserted-by":"publisher","first-page":"e70185","DOI":"10.1111\/cts.70185","volume":"18","author":"AG Hadd","year":"2025","unstructured":"Hadd AG, et al. Establishing a common lexicon for Circulating tumor DNA analysis and molecular residual disease: insights from the BLOODPAC consortium. Clin Transl Sci. 2025;18(3):e70185.","journal-title":"Clin Transl Sci"},{"key":"4238_CR105","doi-asserted-by":"publisher","first-page":"101253","DOI":"10.1016\/j.mam.2024.101253","volume":"96","author":"D Andersson","year":"2024","unstructured":"Andersson D, et al. Principles of digital sequencing using unique molecular identifiers. Mol Aspects Med. 2024;96:101253.","journal-title":"Mol Aspects Med"},{"issue":"5","key":"4238_CR106","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41588-023-01376-0","volume":"55","author":"JH Bae","year":"2023","unstructured":"Bae JH, et al. Single duplex DNA sequencing with CODEC detects mutations with high sensitivity. Nat Genet. 2023;55(5):871\u20139.","journal-title":"Nat Genet"},{"key":"4238_CR107","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez JC, Coombs CC. What\u2019s hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers. Haematologica. 2025;110:505\u201315.","DOI":"10.3324\/haematol.2025.287424"},{"issue":"1","key":"4238_CR108","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41698-025-00921-w","volume":"9","author":"G Arango-Argoty","year":"2025","unstructured":"Arango-Argoty G, et al. An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples. NPJ Precis Oncol. 2025;9(1):147.","journal-title":"NPJ Precis Oncol"},{"key":"4238_CR109","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jlb.2025.100311","volume":"9","author":"DW Brown","year":"2025","unstructured":"Brown DW, et al. Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy. J Liq Biopsy. 2025;9:100311.","journal-title":"J Liq Biopsy"},{"key":"4238_CR110","doi-asserted-by":"crossref","unstructured":"Rhrissorrakrai K et al. Lesion shedding model: unraveling site-specific contributions to ctdna. Brief Bioinform. 2023;24(2):bbad065.","DOI":"10.1093\/bib\/bbad059"},{"issue":"2","key":"4238_CR111","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/OP.23.00495","volume":"20","author":"MLB Peters","year":"2024","unstructured":"Peters MLB, et al. Cost-Effectiveness analysis of screening for pancreatic cancer among High-Risk populations. JCO Oncol Pract. 2024;20(2):278\u201390.","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"4238_CR112","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167\u201377.","journal-title":"Ann Oncol"},{"issue":"11","key":"4238_CR113","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","volume":"14","author":"PJ Mazzone","year":"2024","unstructured":"Mazzone PJ, et al. Clinical validation of a Cell-Free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 2024;14(11):2224\u201342.","journal-title":"Cancer Discov"},{"issue":"1","key":"4238_CR114","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios D, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12(1):5060.","journal-title":"Nat Commun"},{"issue":"6","key":"4238_CR115","doi-asserted-by":"publisher","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, et al. An open-label study of Pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024;9(6):103488.","journal-title":"ESMO Open"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04238-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:03:42Z","timestamp":1773147822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04238-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4238"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04238-1","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}